Unmasking biomarkers in small cell lung cancer: implication for precision oncology

1

Small cell lung cancer (SCLC) is an aggressive cancer with limited treatment options and poor survival rates.
2

Genetic mutations in TP53, RB1, and MYC contribute to SCLC's aggressive nature and treatment resistance.
3

Key regulators such as ASCL1, NEUROD1, and YAP1 are identified for potential precision therapeutic targeting in SCLC.
4

Biomarkers, including genetic and circulating types, enhance early detection and personalized treatment strategies for SCLC.
5

Combining molecular diagnosis with targeted therapies may improve prognosis for patients with SCLC.

Frontiers In Oncology

by Devshree Parganiha, Mohit Joshi, Sivaramasundaram Sankarasubramanian, Sharanya V Pandit, Harishmitha Nagaraj, Naveenkumar Perumal
June 29, 2026

1